CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer.
  
  OVERVIEW OF ACTIVITY
  Lung cancer is a devastating disease with broad-reaching impact on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. Of importance, despite the many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, however, many have renewed optimism that these trends have already started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine. Over the past several years major clinical trials in lung cancer have witnessed a host of promising successes, many of which are already being operationalized in clinical practice. Even so, these achievements will doubtlessly continue to be dissected in the upcoming years and will further challenge the collective understanding of the biology and optimal management of this disease.
  
  These video proceedings from a CME symposium held during the IASLC 2019 North America Conference on Lung Cancer feature presentations and perspectives from leading lung cancer investigators as well as discussion of a case-based survey designed to document lung cancer investigators’ usual approaches to a variety of relevant clinical scenarios. This activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.
  
  LEARNING OBJECTIVES

  • Evaluate existing guideline recommendations regarding the optimal testing platforms and indications for their use in patients with metastatic NSCLC, and use this information to implement a comprehensive approach to biomarker assessment.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for newly diagnosed metastatic NSCLC, and discern how these approaches can be optimally employed in the care of patients.
  • Consider emerging research data and recent FDA authorizations informing the use of immune checkpoint inhibitors alone or in combination with other systemic therapies for patients with newly diagnosed or progressive small cell lung cancer.
  • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors for patients with metastatic NSCLC and an EGFR tumor mutation, and discern how this information should be applied outside of a research setting.
  • Appraise available safety and efficacy data with approved targeted therapies for patients with metastatic NSCLC and an ALK rearrangement, and consider how these agents can be optimally incorporated into current clinical management algorithms.
  • Communicate the clinical relevance of a positive ROS1 mutation test result to appropriate patients with NSCLC, and appreciate available research findings with approved and investigational agents demonstrating efficacy.
  • Assess other oncogenic pathways (ie, BRAF, MET, NTRK, RET) mediating the growth of tumors in unique subsets of lung cancer, and recall emerging data with commercially available and experimental agents exploiting these targets.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  MODERATOR
  
  Joel W Neal, MD, PhD
  Assistant Professor of Medicine
  Division of Oncology
  Stanford Cancer Institute
  Stanford University
  Stanford, California
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, Jounce Therapeutics, Lilly, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, GlaxoSmithKline, Merck, Nektar, Novartis, Roche Laboratories Inc, Takeda Oncology.
  
  FACULTY
  
  Nasser H Hanna, MD
  Professor of Medicine
  Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research
  Indiana University
  Indianapolis, Indiana
  
  Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Merck; Data and Safety Monitoring Board/Committee: BeyondSpring Inc.
  
  Leora Horn, MD, MSc
  Ingram Associate Professor of Cancer Research
  Director, Thoracic Oncology Research Program
  Assistant Vice Chairman for Faculty Development
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Advisory Committee: EMD Serono Inc, Genentech, Xcovery; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, Incyte Corporation, Merck, Pfizer Inc, Roche Laboratories Inc, Tesaro, Xcovery; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Incyte Corporation, Merck, Takeda Oncology, Xcovery; Paid Travel: Bristol-Myers Squibb Company, Xcovery.
  
  Lecia V Sequist, MD, MPH
  Director, Center for Innovation in Early Cancer Detection
  Massachusetts General Hospital Cancer Center
  The Landry Family Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis.
  
  RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Genentech.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: December 2019
  Expiration date: December 2020